Skip to main content

Table 4 Ongoing randomised second-line trials with selected immunotherapeuticsa in recurrent and/or metastatic head and neck cancer (also including nasopharyngeal carcinoma) as of April 2017 (≥ 100 patients)

From: Immunotherapy in head and neck cancer: aiming at EXTREME precision

Trial, ClinicalTrials.gov identifier

Phase

Estimated enrolment

Immunotherapeutic approach

Regimen (treatment arms A, B, C)

Primary completion date

NCT02105636

(CheckMate-141)

III

361d

Anti-PD-1

A: Nivolumab

B: SoC

11/2015

NCT02319044

(CONDOR)b

IIR

240

Anti-PD-L1

Anti-CTLA-4

A: Durvalumab

B: Tremelimumab

C: Durvalumab + tremelimumab

9/2016

NCT02252042

(KEYNOTE-040)

III

466

Anti-PD-1

A: Pembrolizumab

B: SoC

5/2017

NCT02369874

(EAGLE)

III

720

Anti-PD-L1

Anti-CTLA-4

A: Durvalumab

B: Durvalumab + tremelimumab

C: SoC

2/2018

NCT02611960c

(KEYNOTE-122)

IIR

160

Anti-PD-1

A: Pembrolizumab

B: SoC

1/2019

  1. IIR phase II randomised, PD-1 programmed cell death protein-1, PD-L1 programmed cell death ligand-1, CTLA-4 cytotoxic T-lymphocyte antigen-4, SoC Standard of Care
  2. aimmune-modulating agents, vaccines, and adoptive T-cell transfer
  3. bin patients with PD-L1 negative tumours
  4. conly nasopharyngeal cancer
  5. dactual and estimated enrolments were 361 and 506, respectively